U.S. joins global Alzheimer's research push, with annual transparency checks
H.R. 3674 — Global Alzheimer’s Initiative Now Act · Filed by Ami Bera (D-CA) · 6 cosponsors · Introduced Jun 3, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill authorizes the U.S. government to participate in and contribute funding to the Davos Alzheimer's Collaborative (DAC), a public-private partnership working to develop treatments and diagnostics for Alzheimer's disease and dementia globally, with a focus on low- and middle-income countries. The U.S. contribution is capped at 33% of total DAC funding and requires matching funds from other sources; the bill also requires annual reporting to Congress on U.S. participation and financial contributions.
Why we flagged it
The bill's core function is to authorize U.S. participation in a multilateral Alzheimer's research and development initiative, with explicit public-health and global-cooperation framing. It is straightforward health diplomacy legislation.
What the text implies
- The 33% funding cap and matching requirement may limit U.S. influence over DAC governance and research priorities, potentially ceding agenda-setting to private pharmaceutical interests or other nations.
- Annual reporting requirement creates transparency but does not mandate public disclosure of research outcomes or intellectual property arrangements, which could affect U.S. access to resulting treatments.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical research companies; biotech firms developing Alzheimer's diagnostics and treatments; healthcare systems in participating countries